AMP Workshop — Harnessing NGS-based MRD detection: Insights from a retrospective AML cohort study

The emergence of NGS-based MRD technologies offers a significant advantage over existing approaches in hemato-oncology, simultaneously providing lower detection limits and deeper genomic insights.

Hear from Dr. Sean Glenn, Roswell Park Cancer Institute, as he shares his insights using the SureSeq™ Myeloid MRD Panel* in a retrospective cohort study of research specimens collected from patients undergoing AML treatment.

Attendees will learn about the ability of the SureSeq Myeloid MRD Panel to assess residual disease signals as compared to other existing technologies in the field and how targeted NGS-based panels, combined with optimized bioinformatic analysis, can enhance our understanding of AML MRD.

*Research Use Only; Not for Use in Diagnostic Procedures